

Massimo Aglietta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3475557/publications.pdf>

Version: 2024-02-01

354
papers

18,559
citations

17405

63
h-index

16127

124
g-index

356
all docs

356
docs citations

356
times ranked

21894
citing authors

#	ARTICLE	IF	CITATIONS
1	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	6.3	1,752
2	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 773-779.	0.8	1,525
3	Granulocyte- and granulocyte- macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. <i>Nature</i> , 1989, 337, 471-473.	13.7	640
4	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. <i>Annals of Oncology</i> , 2007, 18, 977-984.	0.6	498
5	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
6	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
7	Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood. <i>Blood</i> , 1997, 89, 2644-2653.	0.6	434
8	The release of platelet-activating factor from human endothelial cells in culture. <i>Journal of Immunology</i> , 1983, 131, 2397-403.	0.4	333
9	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. <i>Blood</i> , 1999, 93, 3736-3749.	0.6	296
10	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. <i>Annals of Oncology</i> , 2012, 23, 508-516.	0.6	296
11	Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 744-754.	1.2	289
12	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 161-170.	0.8	283
13	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	5.1	270
14	Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. <i>Haematologica</i> , 2001, 86, 1099-1100.	1.7	231
15	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 67-76.	1.1	225
16	Correlations between diffusion-weighted imaging and breast cancer biomarkers. <i>European Radiology</i> , 2012, 22, 1519-1528.	2.3	206
17	Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.. <i>Journal of Clinical Investigation</i> , 1986, 77, 2027-2033.	3.9	205
18	Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. <i>Lancet Oncology</i> , The, 2013, 14, 663-670.	5.1	165

#	ARTICLE	IF	CITATIONS
19	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2014, 25, 1750-1755.	0.6	164
20	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118.	7.9	159
21	Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 1680-1685.	3.2	151
22	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. <i>BMC Cancer</i> , 2010, 10, 631.	1.1	149
23	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	1.8	149
24	Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. <i>Journal of Immunology</i> , 1987, 139, 2439-46.	0.4	146
25	Transmission of Hepatitis C via Blood Splash into Conjunctiva. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 270-271.	1.5	145
26	High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2150-2156.	0.8	137
27	Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor.. <i>Journal of Clinical Investigation</i> , 1989, 83, 551-557.	3.9	132
28	Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival. <i>Annals of Surgical Oncology</i> , 2006, 13, 1201-1208.	0.7	130
29	Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 673-684.	1.4	124
30	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (VICTORIA-BIL study). <i>Cancer</i> , 2016, 122, 574-581.	2.0	121
31	Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. <i>Oncologist</i> , 2006, 11, 318-324.	1.9	116
32	Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. <i>Leukemia</i> , 1998, 12, 718-727.	3.3	114
33	Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. <i>Blood</i> , 2011, 117, 419-428.	0.6	114
34	TGFÎ± expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005, 24, 3002-3010.	2.6	113
35	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	0.6	113
36	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012, 23, 2072-2077.	0.6	108

#	ARTICLE	IF	CITATIONS
37	Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. <i>International Immunology</i> , 2008, 20, 841-848.	1.8	106
38	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 392-410.	0.8	102
39	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised "GISCAD"™ trial. <i>Annals of Oncology</i> , 2011, 22, 1236-1242.	0.6	98
40	Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.. <i>Journal of Clinical Investigation</i> , 1995, 96, 940-952.	3.9	98
41	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	3.5	97
42	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 257-268.	1.4	96
43	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. <i>Clinical Cancer Research</i> , 2013, 19, 2117-2131.	3.2	96
44	Metastatic breast cancer subtypes and central nervous system metastases. <i>Breast</i> , 2014, 23, 623-628.	0.9	95
45	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544.	0.8	89
46	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. <i>BMC Cancer</i> , 2011, 11, 31.	1.1	86
47	Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. <i>Pharmacological Research Communications</i> , 1986, 18, 133-137.	0.2	85
48	Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. <i>Experimental Hematology</i> , 2003, 31, 261-270.	0.2	85
49	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. <i>Blood</i> , 2002, 100, 4391-4400.	0.6	84
50	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. <i>Clinical Cancer Research</i> , 2005, 11, 490-7.	3.2	83
51	Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. <i>Blood</i> , 2004, 103, 4440-4448.	0.6	81
52	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. <i>Clinical Cancer Research</i> , 2013, 19, 4347-4358.	3.2	81
53	Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. <i>Annals of Oncology</i> , 2022, 33, 1052-1060.	0.6	81
54	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	1.9	79

#	ARTICLE	IF	CITATIONS
55	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 153-164.	1.3	79
56	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 256-267.	4.3	78
57	Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 2308.	1.7	76
58	Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. <i>British Journal of Surgery</i> , 2010, 97, 1354-1362.	0.1	74
59	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 1740-1748.	0.6	74
60	Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. <i>Cancer</i> , 2013, 119, 277-284.	2.0	72
61	Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. <i>Blood</i> , 1995, 86, 4105-4114.	0.6	71
62	Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. <i>British Journal of Surgery</i> , 2006, 93, 1001-1006.	0.1	71
63	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014, 110, 2165-2169.	2.9	69
64	Translocation-Related Sarcomas. <i>Seminars in Oncology</i> , 2009, 36, 312-323.	0.8	67
65	Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. <i>Cancer Research</i> , 2014, 74, 119-129.	0.4	67
66	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. <i>British Journal of Cancer</i> , 2011, 104, 1686-1690.	2.9	65
67	The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results From a Large Retrospective Study. <i>Oncologist</i> , 2012, 17, 1430-1438.	1.9	65
68	Human endothelial cells are targets for platelet-activating factor (PAF). Activation of alpha and beta protein kinase C isozymes in endothelial cells stimulated by PAF. <i>Journal of Biological Chemistry</i> , 1994, 269, 2877-86.	1.6	63
69	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
70	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
71	Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.. <i>Molecular and Cellular Biology</i> , 1986, 6, 1803-1811.	1.1	60
72	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012, 118, 17-26.	2.0	58

#	ARTICLE	IF	CITATIONS
73	Biosynthesis and Release of Platelet-Activating Factor from Human Monocytes. <i>International Archives of Allergy and Immunology</i> , 1983, 70, 245-251.	0.9	57
74	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. <i>Annals of Oncology</i> , 2018, 29, 2288-2295.	0.6	57
75	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820.	1.7	57
76	Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. <i>Seminars in Oncology</i> , 1994, 21, 5-9.	0.8	57
77	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. <i>European Radiology</i> , 2007, 17, 1490-1497.	2.3	56
78	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911.	0.9	55
79	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 445.	3.4	55
80	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169.	1.8	53
81	Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i> , 2009, 115, 2980-2987.	2.0	50
82	Post-Transplant Cyclophosphamide and Tacrolimus/Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 459-466.	2.0	50
83	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
84	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. <i>Molecular Cancer</i> , 2017, 16, 86.	7.9	49
85	In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. <i>Blood</i> , 1991, 77, 1191-1194.	0.6	48
86	A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer. <i>Oncology</i> , 2004, 66, 38-45.	0.9	48
87	Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 831-840.	1.4	48
88	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The GISCAD-alternating schedule study findings. <i>European Journal of Cancer</i> , 2009, 45, 65-73.	1.3	48
89	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 29-40.	1.1	47
90	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. <i>Blood</i> , 2006, 107, 3795-3803.	0.6	46

#	ARTICLE	IF	CITATIONS
91	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. <i>Acta Oncologica</i> , 2007, 46, 664-668.	0.8	46
92	Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer. <i>Oncology</i> , 2005, 68, 493-499.	0.9	44
93	Fluoropyrimidine-induced cardiotoxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 1-10.	2.0	44
94	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 81-96.	0.9	43
95	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. <i>Gynecologic Oncology</i> , 2015, 138, 627-633.	0.6	43
96	Activation of JAK2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 863-872.	0.6	42
97	Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. <i>Clinical Radiology</i> , 2006, 61, 338-347.	0.5	42
98	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011, 22, 1614-1621.	0.6	42
99	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-1 or -2. <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
100	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020, 40, 704-711.	1.9	42
101	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
102	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006, 17, 1479-1488.	0.6	39
103	Biliary tract carcinomas: From chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 136-148.	2.0	39
104	Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1. <i>Cancer Research</i> , 1980, 40, 2507-11.	0.4	39
105	Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?. <i>Journal of Clinical Oncology</i> , 2011, 29, e691-e693.	0.8	38
106	CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. <i>Oncolimmunology</i> , 2018, 7, e1423167.	2.1	38
107	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37
108	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016, 7, 37680-37692.	0.8	37

#	ARTICLE	IF	CITATIONS
109	The development of axonal transport of proteins and glycoproteins in the optic pathway of chick embryos. <i>Brain Research</i> , 1973, 63, 273-284.	1.1	36
110	The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 13-20.	2.9	35
111	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. <i>BMC Cancer</i> , 2016, 16, 90.	1.1	35
112	COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. <i>JCO Oncology Practice</i> , 2020, 16, 295-298.	1.4	35
113	Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1987, 927, 43-54.	1.9	34
114	A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 50-55.	2.1	34
115	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. <i>European Radiology</i> , 2005, 15, 1224-1233.	2.3	34
116	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2277-2288.	3.2	34
117	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839.	1.8	34
118	Met inhibition revokes IFN γ -induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019, 120, 527-536.	2.9	34
119	Fast But Durable Megakaryocyte Repopulation and Platelet Production in NOD/SCID Mice Transplanted with Ex-Vivo Expanded Human Cord Blood CD34+ Cells. <i>Stem Cells</i> , 2004, 22, 135-143.	1.4	33
120	Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 30.	1.3	33
121	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. <i>Tumor Biology</i> , 2016, 37, 4041-4052.	0.8	31
122	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 Antibody. <i>Clinical Cancer Research</i> , 2018, 24, 3377-3385.	3.2	31
123	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
124	Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor- α or interleukin-1 α . <i>European Journal of Immunology</i> , 1994, 24, 3131-3139.	1.6	30
125	Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3871-3872.	0.8	30
126	Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. <i>Cancer</i> , 1993, 72, 2970-2973.	2.0	29

#	ARTICLE	IF	CITATIONS
127	Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiology. <i>European Journal of Clinical Investigation</i> , 1995, 25, 68-70.	1.7	29
128	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. <i>Endocrine-Related Cancer</i> , 2009, 16, 1091-1102.	1.6	29
129	Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Medicine</i> , 2018, 7, 4339-4344.	1.3	29
130	Melanoma Brain Metastases in the Era of Target Therapies: An Overview. <i>Cancers</i> , 2020, 12, 1640.	1.7	29
131	Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. <i>Blood</i> , 1986, 68, 1339-1347.	0.6	28
132	Negative Influence of IL3 on the Expansion of Human Cord Blood In Vivo Long-Term Repopulating Stem Cells. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 945-956.	1.8	28
133	Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 95-97.	0.6	28
134	Poor prognosis osteosarcoma: new therapeutic approach. <i>Bone Marrow Transplantation</i> , 2008, 41, S131-S134.	1.3	28
135	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2017, 78, 122-132.	1.3	28
136	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020, 139, 47-54.	0.9	28
137	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 1261-1267.	2.9	27
138	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 326-335.	2.0	27
139	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
140	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. <i>Cancer</i> , 2013, 119, 3429-3435.	2.0	26
141	Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. <i>Immunotherapy</i> , 2015, 7, 999-1010.	1.0	26
142	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442.	1.1	25
143	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1600-1607.	2.0	25
144	¹⁵³ Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 1899-1905.	0.6	25

#	ARTICLE	IF	CITATIONS
145	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014, 23, 44-49.	0.9	25
146	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	1.3	25
147	Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1596-1601.	0.7	24
148	Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. <i>BMC Research Notes</i> , 2014, 7, 529.	0.6	24
149	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. <i>BMC Cancer</i> , 2015, 15, 374.	1.1	24
150	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020, 26, 6321-6334.	3.2	24
151	The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. <i>Experimental Hematology</i> , 1996, 24, 340-6.	0.2	24
152	Essential thrombocythemia: Impaired regulation of megakaryocyte progenitors. <i>International Journal of Cell Cloning</i> , 1991, 9, 43-56.	1.6	23
153	Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. <i>Acta Radiologica</i> , 2004, 45, 71-74.	0.5	23
154	Anticoagulation for Central Venous Catheters in Patients with Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1362-1363.	13.9	23
155	Screening for the <i>FIGA</i> fusion in biliary tract carcinomas by nested PCR. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 1033-1040.	1.5	23
156	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	1.9	23
157	Incorporating Trastuzumab into the Neoadjuvant Treatment of HER2-Overexpressing Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 77-80.	1.1	21
158	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. <i>Acta Oncologica</i> , 2006, 45, 216-217.	0.8	21
159	An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 640-641.	0.6	21
160	Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. <i>Journal of Immunotherapy</i> , 2012, 35, 579-586.	1.2	21
161	Role of interferon in melanoma: old hopes and new perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 475-483.	1.4	21
162	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018, 11, 42.	1.3	21

#	ARTICLE	IF	CITATIONS
163	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. <i>Cancers</i> , 2019, 11, 519.	1.7	21
164	Vasculogenic potential of long term repopulating cord blood progenitors. <i>FASEB Journal</i> , 2004, 18, 1273-1275.	0.2	20
165	Continuation of Trastuzumab Beyond Disease Progression. <i>Journal of Clinical Oncology</i> , 2005, 23, 2866-2868.	0.8	20
166	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	0.7	20
167	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	1.4	20
168	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. <i>Oncolmmunology</i> , 2018, 7, e1465161.	2.1	20
169	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019, 19, 794.	1.1	20
170	TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17.	1.3	20
171	Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. <i>Current Gene Therapy</i> , 2014, 14, 52-62.	0.9	20
172	Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. <i>Experimental Hematology</i> , 1989, 17, 296-9.	0.2	20
173	Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. <i>Bone Marrow Transplantation</i> , 2001, 27, 517-523.	1.3	19
174	ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. <i>British Journal of Cancer</i> , 2003, 88, 396-400.	2.9	19
175	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. <i>Journal of Clinical Oncology</i> , 2021, 39, 58-58.	0.8	19
176	Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2001, 15, 38-48.	0.7	19
177	Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. <i>British Journal of Haematology</i> , 1991, 79, 451-456.	1.2	18
178	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel. <i>Advances in Therapy</i> , 2011, 28, 684-697.	1.3	18
179	Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 159.	1.0	18
180	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1259-1270.	1.4	18

#	ARTICLE	IF	CITATIONS
181	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016, 14, 119.	1.8	18
182	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 593-601.	1.5	17
183	Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. <i>Experimental Hematology</i> , 2008, 36, 235-243.	0.2	16
184	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , 2013, 48, 414-418.	1.3	16
185	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	2.0	16
186	In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. <i>Leukemia Research</i> , 1985, 9, 879-883.	0.4	15
187	Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl. <i>Leukemia</i> , 1997, 11, 531-540.	3.3	15
188	Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?. <i>Oncology</i> , 2003, 64, 186-188.	0.9	15
189	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020, 12, 1519.	1.7	15
190	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 26181-26191.	0.8	15
191	In vivo priming of human normal neutrophils by granulocyte-macrophage colony stimulating factor: effect on the production of platelet activating factor. <i>British Journal of Haematology</i> , 1990, 75, 333-339.	1.2	14
192	Ex Vivo Expansion of Cord Blood Progenitors. <i>Vox Sanguinis</i> , 1998, 74, 457-462.	0.7	14
193	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. <i>Journal of Biotechnology</i> , 2011, 156, 218-226.	1.9	14
194	Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1528-1538.	1.9	14
195	In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. <i>European Radiology</i> , 2012, 22, 1131-1139.	2.3	14
196	Emerging molecular target antagonists for the treatment of biliary tract cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 63-75.	1.0	14
197	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877.	2.0	14
198	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. <i>Cells</i> , 2021, 10, 543.	1.8	14

#	ARTICLE	IF	CITATIONS
199	Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. <i>Oncotarget</i> , 2016, 7, 52354-52363.	0.8	14
200	Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. <i>Cancer Research</i> , 1986, 46, 1783-7.	0.4	14
201	Ex vivo expansion of hematopoietic cells and their clinical use. <i>Haematologica</i> , 1998, 83, 824-48.	1.7	14
202	The relevance of cell kinetics for optimal scheduling of 1- β -d-Arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML). <i>Cancer Chemotherapy and Pharmacology</i> , 1978, 1, 219-23.	1.1	13
203	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2052-2053.	0.8	13
204	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. <i>BMC Cancer</i> , 2010, 10, 28.	1.1	13
205	Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. <i>BMC Cancer</i> , 2017, 17, 266.	1.1	13
206	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. <i>BMC Genomics</i> , 2018, 19, 440.	1.2	13
207	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019, 18, e394-e401.	1.0	13
208	Androgen receptor status predicts development of brain metastases in ovarian cancers. <i>Oncotarget</i> , 2017, 8, 41143-41153.	0.8	13
209	Detection of basophils growing in semisolid agar culture. <i>Experimental Hematology</i> , 1981, 9, 95-100.	0.2	13
210	Granulocyte-Macrophage colony stimulating factor and interleukin 3: Target cells and kinetics of response in vivo. <i>Stem Cells</i> , 1993, 11, 83-87.	1.4	12
211	The role of cAMP;hyphen;Mpl ligands in the expansion of cord blood hematopoietic progenitors. <i>Stem Cells</i> , 1998, 16, 243-248.	1.4	12
212	Short term treatment with Escheria coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. , 2000, 88, 454-460.		12
213	The involvement of human-nuc gene in polyploidization of K562 cell line. <i>Experimental Hematology</i> , 2000, 28, 1432-1440.	0.2	12
214	Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. <i>Annals of Oncology</i> , 2007, 18, 1963-1968.	0.6	12
215	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. <i>Oncology Letters</i> , 2012, 3, 819-824.	0.8	12
216	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 131.	1.0	12

#	ARTICLE	IF	CITATIONS
217	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 241-245.	0.4	12
218	High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. <i>ESMO Open</i> , 2021, 6, 100133.	2.0	12
219	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. <i>Blood</i> , 1999, 93, 3736-3749.	0.6	12
220	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. <i>PLoS ONE</i> , 2018, 13, e0191593.	1.1	12
221	Flow cytometric detection and quantitative analysis of the GM-CSF receptor in human granulocytes and comparison with the radioligand binding assay. , 1996, 24, 374-381.		11
222	Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study. <i>Bone Marrow Transplantation</i> , 2002, 29, 443-448.	1.3	11
223	Trastuzumab Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2186-2186.	13.9	11
224	Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott-Aldrich Syndrome Gene. <i>Stem Cells</i> , 2009, 27, 2815-2823.	1.4	11
225	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). <i>Medical Oncology</i> , 2013, 30, 581.	1.2	11
226	Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 218-226.	2.0	11
227	Adoptive immunotherapy against sarcomas. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 517-528.	1.4	11
228	HER2 and Central Nervous System Metastasis in Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 232-234.	1.1	10
229	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2566-2567.	0.8	10
230	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. <i>Cancers</i> , 2019, 11, 1547.	1.7	10
231	Post-Transplant Cyclophosphamide and Tacrolimusâ€”Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1173.	1.0	10
232	Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. <i>Oncotarget</i> , 2016, 7, 86766-86780.	0.8	10
233	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 828.	1.0	10
234	Retinoic Acid Enhances the Growth of Only One Subpopulation of Granulomonocyte Precursors. <i>Acta Haematologica</i> , 1984, 71, 97-99.	0.7	9

#	ARTICLE	IF	CITATIONS
235	Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability. <i>Breast Cancer Research and Treatment</i> , 2003, 82, 185-190.	1.1	9
236	Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study. <i>Experimental Hematology</i> , 2005, 33, 1371-1387.	0.2	9
237	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 549-565.	0.9	9
238	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. <i>Molecular Medicine</i> , 2017, 23, 235-246.	1.9	9
239	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	0.9	9
240	Veliparib: a new therapeutic option in ovarian cancer?. <i>Future Oncology</i> , 2019, 15, 1975-1987.	1.1	9
241	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	0.8	9
242	Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. <i>Blood</i> , 1986, 68, 1339-47.	0.6	9
243	Differences in the in vitro growth pattern of fresh and cryopreserved granulo-monopoietic precursors. <i>Cryobiology</i> , 1984, 21, 486-490.	0.3	8
244	Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors. <i>Transplantation Proceedings</i> , 2005, 37, 2664-2666.	0.3	8
245	Serial Transplantations in Nonobese Diabetic/Severe Combined Immunodeficiency Mice of Transduced Human CD34+Cord Blood Cells: Efficient Oncoretroviral Gene Transfer and Ex Vivo Expansion Under Serum-Free Conditions. <i>Stem Cells</i> , 2006, 24, 1201-1212.	1.4	8
246	Sustained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+Cells Transduced with Third-Generation Lentiviral Vectors. <i>Stem Cells</i> , 2008, 26, 1620-1627.	1.4	8
247	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 209.	1.1	8
248	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 93.	1.0	8
249	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672.	1.9	8
250	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. <i>BMC Cancer</i> , 2014, 14, 918.	1.1	8
251	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. <i>BMC Cancer</i> , 2016, 16, 793.	1.1	8
252	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020, 12, 3256.	1.7	8

#	ARTICLE	IF	CITATIONS
253	Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 6478.	1.6	8
254	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. <i>Cancers</i> , 2021, 13, 2051.	1.7	8
255	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	1.3	8
256	MEKâ€“ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. <i>The Hematology Journal</i> , 2002, 3, 105-113.	2.0	8
257	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, <i>Future Trends. Clinical Breast Cancer</i> , 2000, 1, 197-209.	1.1	7
258	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewingâ€™s family tumours. <i>European Journal of Cancer</i> , 2007, 43, 885-890.	1.3	7
259	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. <i>Anti-Cancer Drugs</i> , 2008, 19, 689-696.	0.7	7
260	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2121-2137.	0.9	7
261	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	1.7	7
262	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewingâ€™s Sarcoma and Chondrosarcoma. <i>Cells</i> , 2021, 10, 2893.	1.8	7
263	Short-term effects of colcemid on the rapid axonal transport of proteins in the optic pathway of chick embryos. <i>Experientia</i> , 1973, 29, 1126-1127.	1.2	6
264	H2 receptor antagonists and human granulopoiesis. <i>Experientia</i> , 1985, 41, 375-376.	1.2	6
265	Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. <i>Leukemia Research</i> , 1987, 11, 285-290.	0.4	6
266	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1991, 52, 63-69.	1.0	6
267	A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. <i>European Journal of Cancer</i> , 1995, 31, 46-49.	1.3	6
268	Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1145-1145.	0.8	6
269	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156.	0.9	6
270	Gingival metastasis of a radiotherapy-induced breast angiosarcoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 1112-1117.	0.7	6

#	ARTICLE	IF	CITATIONS
271	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1491-1500.	1.4	6
272	Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. <i>Future Oncology</i> , 2018, 14, 443-448.	1.1	6
273	Effectiveness of dabrafenib in the treatment of patients with BRAF V600A mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	0.6	6
274	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096872.	1.4	6
275	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020, 13, 53.	1.3	6
276	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	1.4	6
277	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	0.6	6
278	Human GM-CSF in vivo: Identification of the target cells and of their kinetics of response. <i>International Journal of Cell Cloning</i> , 1990, 8, 283-292.	1.6	5
279	Ex vivo expansion of megakaryocytes. <i>Transfusion Science</i> , 2000, 22, 107-110.	0.6	5
280	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. <i>Cancer</i> , 2005, 103, 1314-1315.	2.0	5
281	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072.	0.9	5
282	Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 68-74.	2.0	5
283	Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. <i>Journal of Chemotherapy</i> , 2006, 18, 90-97.	0.7	5
284	Trastuzumab Beyond Disease Progression: Case Closed?. <i>Journal of Clinical Oncology</i> , 2009, 27, e121-e122.	0.8	5
285	Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature. <i>Oncology Research</i> , 2012, 20, 483-490.	0.6	5
286	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	1.0	5
287	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 191-198.	1.1	5
288	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1451-1463.	0.9	5

#	ARTICLE	IF	CITATIONS
289	Preventing Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2180-2181.	13.9	5
290	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. <i>Gynecologic Oncology</i> , 2021, 162, 80-87.	0.6	5
291	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021, 16, 789-799.	1.7	5
292	GM-CSF: intravenous versus subcutaneous treatment. <i>Leukemia</i> , 1990, 4, 523.	3.3	5
293	Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. <i>Haematologica</i> , 2003, 88, ECR16.	1.7	5
294	Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM). <i>Experientia</i> , 1981, 37, 1340-1341.	1.2	4
295	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. <i>Cancer Genetics and Cytogenetics</i> , 1991, 55, 235-241.	1.0	4
296	MYELOFIBROSIS AND PROSTAGLANDINS: EFFECT OF PROSTAGLANDIN E1 ON COLONY-FORMING CELLS (CFU-GM). <i>British Journal of Haematology</i> , 2008, 48, 167-169.	1.2	4
297	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP). , 2013, 1, .		4
298	Treating breast cancer with cell-based approaches: an overview. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1255-1264.	1.4	4
299	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. <i>Melanoma Research</i> , 2018, 28, 143-146.	0.6	4
300	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. <i>Cancers</i> , 2019, 11, 369.	1.7	4
301	Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. <i>Cancers</i> , 2019, 11, 454.	1.7	4
302	Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. <i>BMC Cancer</i> , 2021, 21, 865.	1.1	4
303	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10009-10009.	0.8	4
304	Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 211-222.	0.9	4
305	Targeted agents: how can we improve the outcome in biliary tract cancer?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 31-3.	0.7	4
306	Treatment of metastatic melanoma: a multidisciplinary approach. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 241-261.	0.1	4

#	ARTICLE	IF	CITATIONS
307	Normal and leukaemic granulopoiesis. <i>Haematologica</i> , 1981, 66, 1-17.	1.7	4
308	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 771418.	1.3	4
309	Effect of Hemopoietic Growth Factors on the Proliferation of Acute Myeloid and Lymphoid Leukemias. <i>Leukemia and Lymphoma</i> , 1990, 2, 207-214.	0.6	3
310	Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 655-666.	1.4	3
311	Duration of trastuzumab for HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 678-679.	5.1	3
312	Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. <i>Oncolmmunology</i> , 2014, 3, e28269.	2.1	3
313	“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 17-24.	2.0	3
314	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2021, 9, 235.	2.1	3
315	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019, 37, 219-219.	0.8	3
316	Autologous Bone Marrow Transplantation in Acute Leukemia. <i>Acta Haematologica</i> , 1987, 78, 190-193.	0.7	2
317	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 398-399.	4.3	2
318	Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. <i>Journal of Translational Medicine</i> , 2015, 13, O1.	1.8	2
319	Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. <i>Future Oncology</i> , 2020, 16, 15-19.	1.1	2
320	Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. <i>Cancers</i> , 2021, 13, 2302.	1.7	2
321	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta OncolÃ³gica</i> , 2021, 60, 1317-1324.	0.8	2
322	Responsiveness to Prostaglandin E₁ of Different Subtypes of Normal and Pathological Committed Granulomonopoietic Precursors. <i>Acta Haematologica</i> , 1983, 69, 376-381.	0.7	2
323	Prostaglandins and myelopoiesis: Effect of prostaglandin E on normal and chronic myeloid leukemia colony forming cells (CFU-GM) subpopulations. <i>Cell Biology International Reports</i> , 1981, 5, 836.	0.7	1
324	Human gamma interferon modifies C-myc expression and growth pattern of U937 cell line but not of its subclone 1937. <i>Cell Biology International Reports</i> , 1986, 10, 467.	0.7	1

#	ARTICLE	IF	CITATIONS
325	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. <i>Oncologist</i> , 2011, 16, 534-536.	1.9	1
326	What can we learn from the ZOOM trial? Authors' reply. <i>Lancet Oncology</i> , The, 2013, 14, e388-e390.	5.1	1
327	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. <i>Chronobiology International</i> , 2015, 32, 1359-1366.	0.9	1
328	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650.	0.8	1
329	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132.	0.7	1
330	Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). <i>Journal of Clinical Oncology</i> , 2004, 22, 9021-9021.	0.8	1
331	Effect of AZD0530 (saracatinib) on biliary cancer cell motility and invasion.. <i>Journal of Clinical Oncology</i> , 2011, 29, 231-231.	0.8	1
332	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. <i>ESMO Open</i> , 2022, 7, 100431.	2.0	1
333	Translocation of the c-myc oncogene 3' to the immunoglobulin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma. <i>Cell Biology International Reports</i> , 1986, 10, 148-148.	0.7	0
334	7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. <i>Cytotechnology</i> , 1987, 1, 37-40.	0.7	0
335	Effect of interferon-gamma on hla class II antigen expression and sensitivity to prostaglandin E1 by normal and leukemic myeloid progenitors. <i>Leukemia Research</i> , 1988, 12, 299-303.	0.4	0
336	Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1990, 3, 61-66.	0.6	0
337	Haemopoietic growth factors in oncology. <i>Pharmacological Research</i> , 1992, 26, 80-81.	3.1	0
338	GM-CSF and dose escalation of chemotherapy. <i>Annals of Oncology</i> , 1994, 5, 663.	0.6	0
339	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1179-1188.	0.9	0
340	Reply to A. Sánchez-Muñoz et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e257-e258.	0.8	0
341	Anthracycline-based adjuvant chemotherapy in breast cancer. <i>Lancet</i> , The, 2010, 375, 1871.	6.3	0
342	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177.	0.2	0

#	ARTICLE	IF	CITATIONS
343	Imaging as a potential tool for subtyping breast cancer. <i>Imaging in Medicine</i> , 2012, 4, 577-579.	0.0	0
344	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. <i>Immunotherapy</i> , 2018, 10, 753-767.	1.0	0
345	Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. <i>Acta Haematologica</i> , 2020, 143, 481-485.	0.7	0
346	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	0
347	Preoperation Chemotherapy. <i>Updates in Surgery Series</i> , 2011, , 75-100.	0.0	0
348	Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).. <i>Journal of Clinical Oncology</i> , 2012, 30, e15073-e15073.	0.8	0
349	Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemiaâ€”Mafosfamide Italian Study Group. <i>Plant Systematics and Evolution Supplementum = Entwicklungsgeschichte Und Systematik Der Pflanzen Supplementum</i> , 1988, , 89-93.	1.5	0
350	Role of Hematopoietic Growth Factors on the ex Vivo Expansion of Primitive Cord Blood Stem Cells. , 1999, , 39-50.		0
351	Improvement of metastatic colorectal cancer patient survival: Single institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15633-e15633.	0.8	0
352	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. <i>Transplantology</i> , 2022, 3, 51-67.	0.3	0
353	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomasâ€”A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0
354	Atypical myeloproliferative disorder associated with a 21 trisomic clone. <i>Research in Clinic and Laboratory</i> , 1981, 11, 111-115.	0.3	0